Study Rationale:
Parkinson’s disease is a progressive brain disorder in which dopamine-producing nerve cells gradually die, leading to worsening movement and other symptoms. Research shows that overactive LRRK2 — an enzyme linked to both inherited and non-inherited forms of Parkinson’s — may drive this damage. The LARKIN project is based on the idea that blocking this overactive enzyme with the investigational oral drug OPM-201 could help protect brain cells and potentially slow disease progression, moving beyond treating symptoms alone.
Hypothesis:
This study will help prove that safely and selectively inhibiting the overactive LRRK2 enzyme with the oral drug OPM-201 can reduce harmful biological activity linked to Parkinson’s disease and, by protecting vulnerable dopamine-producing brain cells, potentially slow or modify the progression of the disease rather than only treating its symptoms.
Study Design:
We will prepare OPM-201 for the next stage of testing by making clinical-grade drug supply for a Phase 1b study in people with Parkinson’s disease, where the medicine will be taken for several weeks and researchers will track safety, dosing, and biomarkers that show LRRK2 activity is being reduced. In parallel, we will run a required 39-week long-term safety study in animals, with careful monitoring and a recovery period to see if any effects are reversible. Together, these steps provide the evidence regulators need to support longer patient trials (clinical Phase 2 and beyond).
Impact on Diagnosis/Treatment of Parkinson’s disease:
Current Parkinson’s disease treatments relieve symptoms but do not slow progression. A safe, effective LRRK2 inhibitor could shift care toward disease modification, preserving mobility and independence, delaying advanced therapies, and easing caregiver burden.
Next Steps for Development:
If successful, the next steps would include advancing the LRRK2 inhibitor into larger, late-stage clinical trials to confirm efficacy, safety, and long-term disease-modifying effects in broader Parkinson’s populations. In parallel, regulatory engagement and biomarker validation would support patient stratification and eventual submission for marketing authorization.